Lipid Nanoparticle (LNP) News Brief | Jun 23 – Jun 30 2025

Brief Summaries

AbbVie: To acquire Capstan Therapeutics for up to $2.1 billion, adding targeted LNP (tLNP) in vivo CAR-T technology to its immunology pipeline.

CRISPR Therapeutics: Phase 1 data showed LNP-delivered CRISPR candidate CTX310 cuts triglycerides and LDL by up to 82% and 86%, respectively.

University of Pennsylvania–Genevant (Nature Nanotechnology): PEG-lipid ratio and phospholipid choice fine-tune mRNA-LNP adjuvanticity, guiding vaccine design.

Ludwig-Maximilians-Universität München: Helper-lipid selection (DOPE vs DSPC) dictates siRNA/mRNA-LNP performance for pulmonary delivery.

UCL & University of Sheffield: Unveiled continuous-flow encapsulation plus single-pass TFF, boosting mRNA-LNP production efficiency.

RSC Materials Biology: Zeolitic-imidazolate framework (ZIF-8) coating triples–octuples mRNA-LNP transfection efficiency in vitro.

KAIST-led team (J Controlled Release): Co-delivered IL-12 mRNA and indoximod prodrug via PreciGenome NanoGenerator-made LNPs heightens antitumor T-cell responses.

Detailed Summaries

AbbVie to Acquire Capstan Therapeutics

AbbVie announced a definitive agreement to buy Capstan Therapeutics for up to $2.1 billion cash, gaining CPTX2309, a Phase 1 in vivo anti-CD19 CAR-T therapy encoded in targeted LNPs that transiently reprogram cytotoxic T-cells to deplete pathogenic B-cells in autoimmune diseases. The deal also hands Capstan’s CellSeeker tLNP platform to AbbVie, broadening its immunology franchise.

Release date: 30 Jun 2025

Link: https://www.prnewswire.com/news-releases/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology-302494390.html

Locations: North Chicago, IL (AbbVie); San Diego, CA (Capstan), USA

Phase 1 Update on CRISPR Therapeutics’ CTX310

CRISPR Therapeutics reported additional Phase 1 results showing liver-targeted LNP delivery of CRISPR/Cas9 editing (ANGPTL3) produced dose-dependent lipid reductions—up to 82% triglycerides and 86% LDL—with no serious safety findings. Complete data will be presented H2 2025.

Release date: 26 Jun 2025

Link: https://www.globenewswire.com/news-release/2025/06/26/3105698/0/en/CRISPR-Therapeutics-Reports-Positive-Additional-Phase-1-Data-for-CTX310-Targeting-ANGPTL3-and-Provides-Update-on-In-Vivo-Cardiovascular-Pipeline.html

Locations: Zug, Switzerland & Boston, MA, USA

Tailoring LNP Adjuvanticity (Nature Nanotechnology)

Researchers from the University of Pennsylvania and Genevant demonstrated that modifying PEG-lipid ratios and swapping phospholipids markedly alters biodistribution and immune-response quality of four-component mRNA-LNP vaccines, offering a rational route to customize cellular vs humoral immunity.

Release date: 23 Jun 2025

Link: https://pubmed.ncbi.nlm.nih.gov/40550975/

Authors (corresponding): Norbert Pardi, Máté Vadovics et al.

Locations: Philadelphia, PA, USA; Vancouver, BC, Canada; Los Angeles, CA, USA; Szeged, Hungary; Shanghai, China

Helper-Lipid Choice Governs Pulmonary LNP Delivery (Eur J Pharm Sci)

Using air–liquid interface lung models, LMU-Munich scientists showed DOPE- vs DSPC-containing LNPs differ in mucus penetration, protein-corona makeup and achieve 24–42% gene silencing; insights guide respiratory RNA therapeutics.

Release date: 24 Jun 2025

Link: https://pubmed.ncbi.nlm.nih.gov/40571267/

Authors: Stina Rademacker, Simone Carneiro et al.

Locations: Munich & Planegg-Martinsried, Germany; Ludwigshafen, Germany

Continuous mRNA-LNP Manufacturing Platform

UCL and University of Sheffield engineers integrated microfluidic encapsulation, real-time DLS monitoring and single-pass TFF, achieving 95% encapsulation, 105 nm particle size (PDI 0.1) and 90% recovery—advancing scalable vaccine production.

Release date: 25 Jun 2025

Link: https://pubmed.ncbi.nlm.nih.gov/40578454/

Authors: Ehsan Nourafkan, Zoltán Kis et al.

Locations: London & Sheffield, UK

MOF-Shelled mRNA-LNPs Boost Transfection (RSC)

A study in Journal of Materials Chemistry B reports encapsulating mRNA-LNPs inside ZIF-8 metal–organic frameworks preserved particle integrity and improved protein expression three- to eight-fold in HEK-293 and HCT-116 cells, spotlighting MOFs as add-ons to current LNP tech.

Release date: 25 Jun 2025

Link: https://pubs.rsc.org/en/content/articlelanding/2025/tb/d4tb02101k

Authors: Ruhani Singh, Kerri Bruce, et al.

LNP Co-delivery of IL-12 mRNA + Indoximod Prodrug (J Controlled Release)

KAIST-led researchers formulated LNPs using PreciGenome’s NanoGenerator, loading a cholesterol-linked indoximod prodrug alongside IL-12 mRNA. In tumor models, the LNPs reprogrammed macrophages, elevated IFN-γ and TNF-α, and overcame IDO-mediated immunosuppression, amplifying CD8⁺ T-cell antitumor activity.

Release date: 18 Jun 2025

Link: https://pubmed.ncbi.nlm.nih.gov/40541741/

Authors: Heewon Park et al.

Locations: Daejeon, Chungju & Seoul, Republic of Korea